Literature DB >> 21257284

Clinical outcomes and implications of failed infrainguinal endovascular stents.

Ilia Gur1, William Lee, Gabriel Akopian, Vincent L Rowe, Fred A Weaver, Steven G Katz.   

Abstract

OBJECTIVE: While the influence of initial TransAtlantic InterSociety Consensus (TASC) II classification has been clearly shown to influence the primary patency of infrainguinal stenting procedures, its effect on outcomes once stent failure has occurred is less well documented. It is the objective of this paper to determine whether clinical outcomes and implications of anatomic stent failure vary according to initial TASC II classification.
METHODS: Results were analyzed by TASC II classification. Kaplan-Meier survival curves were plotted and differences between groups tested by log-rank method. A Cox proportional hazards regression model was used to perform the multivariate analysis.
RESULTS: During a 5-year period, 239 angioplasties and stents were performed in 192 patients. Primary patency was lost in 69 stented arteries. Failure was due to one or more hemodynamically significant stenoses in 43 patients, and occlusion in 26 patients. After primary stenting, limbs initially classified as TASC C and D were more likely to fail with occlusion (P < .0001), require open operation (P = .032), or lose run-off vessels (P = .0034) than those classified as TASC A or B. In two patients initially classified as TASC C, stent failure changed the level of open operation to a more distal site. Percutaneous reintervention was performed on 35 limbs. Successful reintervention improved the patency of TASC A and B lesions to 92%, 85%, and 64% and TASC C and D lesions to 78%, 72%, and 50% at 12, 24, and 36 months, respectively. Initial TASC classification was highly predictive of first anatomic failure (P < .0001), but it did not predict the durability of subsequent catheter based reintervention (P = .32). Ten patients with stent failure required operation, and five underwent amputation; all had failed with occlusion. Overall limb salvage was 89% and peri-procedural mortality was 0.4%.
CONCLUSIONS: Following primary stenting of the superficial femoral artery (SFA) and popliteal artery, lesions classified as TASC C or D are more likely to fail with occlusion, lose run-off vessels, and alter the site of subsequent open operation than their TASC A and B counterparts. Although these complications are infrequent, they may negatively impact later attempts at revascularization, and this must be considered when deciding upon the proper treatment strategy for patients with infrainguinal occlusive disease.
Copyright © 2011 Society for Vascular Surgery. Published by Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21257284     DOI: 10.1016/j.jvs.2010.09.069

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  10 in total

1.  Ankle arthroscopy to manage sequelae after ankle fractures.

Authors:  Edward J C Dawe; Christopher P Jukes; Kumar Ganesan; Alexander Wee; Nikolaos Gougoulias
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2014-06-24       Impact factor: 4.342

2.  Ten years after arterial bypass surgery for claudication: venous bypass is the primary procedure for TASC C and D lesions.

Authors:  Thomas Eugster; Regula Marti; Lorenz Gurke; Peter Stierli
Journal:  World J Surg       Date:  2011-10       Impact factor: 3.352

3.  Nitinol self-expanding stents vs. balloon angioplasty for very long femoropopliteal lesions.

Authors:  Ehrin J Armstrong; Haseeb Saeed; Bejan Alvandi; Satinder Singh; Gagan D Singh; Khung Keong Yeo; David Anderson; Gregory G Westin; David L Dawson; William C Pevec; John R Laird
Journal:  J Endovasc Ther       Date:  2014-02       Impact factor: 3.487

4.  Long-Term Patency and Clinical Outcomes of Nitinol Stenting for Femoropopliteal Atherosclerotic Disease.

Authors:  Sherwin Abdoli; Steven Katz; Christian Ochoa
Journal:  Ann Vasc Surg       Date:  2019-11-06       Impact factor: 1.607

5.  The association between periprocedural factors and the late outcome of percutaneous stenting of lower extremity arteries. A retrospective cohort study.

Authors:  Paweł Grzelązka; Klaudia Koza; Adrianna Trofimiuk; Karol Suppan; Marcin Wasielewski; Joanna Wiśniewska; Jacek Budzyński
Journal:  Postepy Kardiol Interwencyjnej       Date:  2015-06-22       Impact factor: 1.426

6.  Distinct gene expression profiles associated with Notch ligands Delta-like 4 and Jagged1 in plaque material from peripheral artery disease patients: a pilot study.

Authors:  Giorgio Aquila; Cinzia Fortini; Antonio Pannuti; Serena Delbue; Micaela Pannella; Marco Bruno Morelli; Cristiana Caliceti; Fausto Castriota; Monica de Mattei; Alessia Ongaro; Agnese Pellati; Pasquale Ferrante; Lucio Miele; Luigi Tavazzi; Roberto Ferrari; Paola Rizzo; Alberto Cremonesi
Journal:  J Transl Med       Date:  2017-05-04       Impact factor: 5.531

7.  Excimer laser atherectomy combined with drug-coated balloon angioplasty for the treatment of chronic obstructive femoropopliteal arterial disease.

Authors:  Hui Liu; Yan Gu; Sen Yang; Ju He; Fuxian Zhang
Journal:  Exp Ther Med       Date:  2019-12-20       Impact factor: 2.447

8.  Network meta-analysis of drug-coated balloon angioplasty versus primary nitinol stenting for femoropopliteal atherosclerotic disease.

Authors:  Sherwin Abdoli; Melissa Mert; William M Lee; Christian J Ochoa; Steven G Katz
Journal:  J Vasc Surg       Date:  2020-11-26       Impact factor: 4.268

9.  Growing impact of restenosis on the surgical treatment of peripheral arterial disease.

Authors:  Douglas W Jones; Andres Schanzer; Yuanyuan Zhao; Todd A MacKenzie; Brian W Nolan; Michael S Conte; Philip P Goodney
Journal:  J Am Heart Assoc       Date:  2013-11-25       Impact factor: 5.501

10.  α-Hydroxybutyrate dehydrogenase is associated with atherothrombotic events following infrainguinal angioplasty and stenting.

Authors:  Silvia Lee; Renate Koppensteiner; Christoph W Kopp; Thomas Gremmel
Journal:  Sci Rep       Date:  2019-12-03       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.